focus -WSS

focus

author：hotspot 2025-09-28 15:06:53 - browse：66

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

focus

WSS

What the US credit downgrade means for the economy, your finances

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Trump indictment: Who are the 'co

What the US credit downgrade means for the economy, your finances

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

focus

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New safety details link Apellis eye drug to rare cases of blindness

Hollywood unions extend contract negotiations for actors

At ASCO, AstraZeneca reports strong data for breast cancer drug

In age of alternative facts, a scholarly course on calling out crap

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

New air purifier tech could be key to improving indoor air quality

EQRx, failed developer of low

Apple is now the first public company to be valued at $3 trillion

Adults seen as increasingly susceptible to measles

leisure time

Intellia reports positive results for its CRISPR

National panel will explore requiring free Covid tests

EQRx, failed developer of low

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

What the US credit downgrade means for the economy, your finances

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

hotspot

focus

entertainment